Printer Friendly

Grant supports company's R&D of therapies for type 1 diabetes.

SAN DIEGO, Calif., February 23, 2017 -- Beyond Type 1, a not-for-profit advocacy and education group for Type 1 diabetics, has awarded a grant to ViaCyte, Inc., a privately-held regenerative medicine company, to support development of a cure for Type 1 and other insulin-requiring diabetes.

For more than a decade, ViaCyte has been developing innovative stem cell-derived cell replacement therapies with a focus on the treatment of insulin-requiring diabetes.

The company's pluripotent stem cell-derived islet cell replacement therapy, the PEC-Direct product candidate, has the potential to be a breakthrough treatment for high-risk Type 1 diabetes.

The PEC-Direct product candidate is expected to begin clinical trials this year and is likely to be the company's first approved product.

ViaCyte's PEC-Encap (also known as VC-01) product candidate delivers the same cell therapy as the PEC-Direct product candidate but in a delivery device designed to protect the cells from the patient's immune system, and therefore will not require immunosuppressant drugs commonly used for organ and tissue transplants.

The PEC-Encap product candidate is being developed to treat all patients with diabetes who use insulin to control their disease.

Preliminary clinical results with the PEC-Encap product candidate have provided early indications of the potential of the approach.

"Beyond Type 1 views ViaCyte's products as potentially game-changing for those suffering with Type 1 diabetes, and seeks to promote their continued safe and efficient development," said CEO Sarah Lucas. "ViaCyte's mission to create a functional cure for Type 1 diabetes is well-aligned with Beyond Type 1's goals."

All funds donated to Beyond Type 1 can be used to directly support the portfolio of partner organizations.

Beyond Type 1 creates and funds a portfolio of programs, technologies, and innovations that those living with Type 1 diabetes need to manage, live, and thrive.



COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Grants & Contracts
Publication:Stem Cell Business News
Date:Mar 6, 2017
Previous Article:$12.2M grant from CIRM supports phase 2 trial of diabetes treatment.
Next Article:U.S. patent covers neuralstem's small molecule compound.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters